WPD Pharmaceuticals Inc. (C:WBIO)
Business Focus: Bio Therapeutic Drugs
You may also be interested in
Insider Filings
Latest 10 SEDI filings for WBIO within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
See Short Report
Loading...
Company News
Sep 20, 2022 19:36 ET
WPD Pharmaceuticals Board of Directors Approved the Raise of WPD Poland's Share Capital
Vancouver, British Columbia--(Newsfile Corp. - September 20, 2022) - WPD Pharmaceuticals Inc. (CSE: WBIO) (FSE: 8SV1) (the "Company" or "WPD") a clinical-stage pharmaceutical company announces that the Company's Board of Directors (the "Board") has approved the raise of WPD Pharmaceuticals Sp. z o.o. ("WPD Poland"), the Polish subsidiary of the Company share capital from PLN 400,000 to PLN 2,100,000, that is by the amount of PLN 1,700,000, by establishment of 34,000 new, equal and indivisible shares of the nominal value of PLN 50 each and the total nominal value of PLN 1,700,000. Raise of WPD Poland's share capital is the second step of a plan to restructure WPD Poland, which the company announced on February 9, 2022.
Jul 11, 2022 12:10 ET
CSE Bulletin: Suspensions (MCCN, MEAL, WBIO, TELE, GBMC, CBDN)
Toronto, Ontario--(Newsfile Corp. - Le 11 juillet/July 2022) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or more securities commissions.
Valuation Ratios
Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
5.20
3.83
Price to Book - most recent quarter
--
1.55
2.08
Price to Cash Flow per share - TTM
--
8.62
9.68
Price to Free Cash Flow per share - TTM
--
5.94
14.80
Short Report
| Date | Number of Shares Shorted | Net Change |
|---|---|---|
| Dec 31, 1969 | 0 | 0 |
| Dec 31, 1969 | 0 | 0 |
| Dec 31, 1969 | 0 | 0 |
Business Summary
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.
